Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph.D., Director of Corporate Development for Onconova, will present a high-level overview of the Company's narazaciclib program at the Next Generation Kinase Inhibitors Summit on March 30, 2022, at 2:00 p.m. ET.

Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit

Onconova Therapeutics' (ONTX) CEO Steve Fruchtman on Q4 2021 Results - Earnings Call Transcript

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022

NEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10, 2022, through January 13, 2022.

Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development.

Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

Onconova Therapeutics, Inc.'s (ONTX) CEO Steve Fruchtman on Q3 2021 Results - Earnings Call Transcript

Onconova Therapeutics (NASDAQ:ONTX) reported its Q3 earnings results on Thursday, November 11, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Recap: Onconova Therapeutics Q3 Earnings

Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Onconova Therapeutics (NASDAQ:ONTX) is set to give its latest quarterly earnings report on Thursday, 2021-11-11. Here's what investors need to know before the announcement.

Earnings Outlook For Onconova Therapeutics

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the closing of its previously announced underwritten public offering. A total of 5,000,000 shares of its common stock were sold at a public offering price of $4.20 per share. The gross proceeds of the offering to the Company are $21 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Onconova granted the underwriters a thirty-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock

Investors need to pay close attention to Onconova (ONTX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Onconova (ONTX) Stock?

Onconova Therapeutics Inc (NASDAQ: ONTX) has priced an underwritten public offering of 5 million shares at $4.20 for gross proceeds of $21 million. The offer price represents an almost 17% discount at the last close price of $5.11 on Thursday.

Onconova Therapeutics Raises $21M Via Equity At 17% Discount

NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $4.20 per share. The gross proceeds of the offering to the Company are expected to be $21 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Onconova granted the underwriters a thirty-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock

NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Onconova. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Onconova intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.

Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) is trading at over 25% during intraday trading today. This is why it happened.

ONTX Stock: Why It Significantly Increased Today

Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares are trading higher after the company reported preliminary data from a Phase 1/2 a trial of rigosertib plus immune checkpoint inhibitor nivolumab, which are being presented at the 3rd Annual RAS Targeted Drug Development Summit. Onconova Therapeutics is currently up 32.3% to a price of $6.48.

Why Onconova Therapeutics Shares Are Surging Today

Today, Oncova Therapeutics announced some positive preliminary trial results from one of its core cancer drugs, sending ONTX stock higher. The post ONTX Stock Is Soaring 25% on This Big Cancer Drug Update appeared first on InvestorPlace.

ONTX Stock Is Soaring 25% on This Big Cancer Drug Update

Onconova Therapeutics Inc (NASDAQ: ONTX) has announced preliminary data from Phase 1/2a trial of rigosertib plus Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in advanced KRAS mutated non-small cell lung cancer (NSCLC).  The trial included patients who failed two or more lines of prior therapy, and all have failed immune checkpoint inhibitors in various combinations.

Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 3.57% and 35.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Tops Revenue Estimates

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2021 Results - Earnings Call Transcript

Shares of Onconova Therapeutics (NASDAQ:ONTX) moved higher by 2.1% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 575.00% over the past year to ($0.27), which beat the estimate of ($0.28).

News for Onconova Therapeutics Stock (ONTX)